| Dissolution media simulating the intralumenal composition of the small intestine: physiological issues and practical aspects M Vertzoni, N Fotaki, E Nicolaides, C Reppas, E Kostewicz, E Stippler, ... Journal of pharmacy and pharmacology 56 (4), 453-462, 2004 | 283 | 2004 |
| Biorelevant dissolution methods and their applications in in vitro-in vivo correlations for oral formulations N Fotaki, M Vertzoni The Open Drug Delivery Journal 4 (1), 2010 | 139 | 2010 |
| Paediatric oral biopharmaceutics: key considerations and current challenges HK Batchelor, N Fotaki, S Klein Advanced drug delivery reviews 73, 102-126, 2014 | 136 | 2014 |
| Flow-through cell apparatus (USP apparatus 4): Operation and features N Fotaki Dissolution Technol 18 (4), 46-49, 2011 | 105 | 2011 |
| Current challenges and future perspectives in oral absorption research: An opinion of the UNGAP network Z Vinarov, B Abrahamsson, P Artursson, H Batchelor, P Berben, ... Advanced Drug Delivery Reviews 171, 289-331, 2021 | 98 | 2021 |
| Biopharmaceutical aspects and implications of excipient variability in drug product performance P Zarmpi, T Flanagan, E Meehan, J Mann, N Fotaki European Journal of Pharmaceutics and Biopharmaceutics 111, 1-15, 2017 | 96 | 2017 |
| A comparative study of different release apparatus in generating in vitro–in vivo correlations for extended release formulations N Fotaki, A Aivaliotis, J Butler, J Dressman, M Fischbach, J Hempenstall, ... European journal of pharmaceutics and biopharmaceutics 73 (1), 115-120, 2009 | 91 | 2009 |
| Biorelevant dissolution: methodology and application in drug development Q Wang, N Fotaki, Y Mao Dissolution Technol 16 (3), 6-12, 2009 | 79 | 2009 |
| Enhanced paracellular transport of insulin can be achieved via transient induction of myosin light chain phosphorylation A Taverner, R Dondi, K Almansour, F Laurent, SE Owens, IM Eggleston, ... Journal of Controlled Release 210, 189-197, 2015 | 75 | 2015 |
| In vitro versus canine data for predicting input profiles of isosorbide-5-mononitrate from oral extended release products on a confidence interval basis N Fotaki, M Symillides, C Reppas European journal of pharmaceutical sciences 24 (1), 115-122, 2005 | 73 | 2005 |
| Impact of gastrointestinal disease states on oral drug absorption–implications for formulation design–a PEARRL review A Effinger, CM O'Driscoll, M McAllister, N Fotaki Journal of Pharmacy and Pharmacology 71 (4), 674-698, 2019 | 71 | 2019 |
| Predictive models for oral drug absorption: from in silico methods to integrated dynamical models A Dokoumetzidis, L Kalantzi, N Fotaki Expert opinion on drug metabolism & toxicology 3 (4), 491-505, 2007 | 70 | 2007 |
| Establishing virtual bioequivalence and clinically relevant specifications using in vitro biorelevant dissolution testing and physiologically-based population pharmacokinetic … I Loisios-Konstantinidis, R Cristofoletti, N Fotaki, DB Turner, J Dressman European Journal of Pharmaceutical Sciences 143, 105170, 2020 | 65 | 2020 |
| Pharmaceutical characterisation and evaluation of cocrystals: importance of in vitro dissolution conditions and type of coformer I Tomaszewska, S Karki, J Shur, R Price, N Fotaki International journal of pharmaceutics 453 (2), 380-388, 2013 | 65 | 2013 |
| Assessment of age-related changes in pediatric gastrointestinal solubility AR Maharaj, AN Edginton, N Fotaki Pharmaceutical research 33, 52-71, 2016 | 59 | 2016 |
| The flow through cell methodology in the evaluation of intralumenal drug release characteristics N Fotaki, C Reppas Dissolution Technol 12 (2), 17-21, 2005 | 53 | 2005 |
| Canine versus in vitro data for predicting input profiles of l-sulpiride after oral administration N Fotaki, M Symillides, C Reppas European journal of pharmaceutical sciences 26 (3-4), 324-333, 2005 | 52 | 2005 |
| BU08073 a buprenorphine analogue with partial agonist activity at μ‐receptors in vitro but long‐lasting opioid antagonist activity in vivo in mice TV Khroyan, J Wu, WE Polgar, G Cami‐Kobeci, N Fotaki, SM Husbands, ... British journal of pharmacology 172 (2), 668-680, 2015 | 47 | 2015 |
| Biopharmaceutical understanding of excipient variability on drug apparent solubility based on drug physicochemical properties. Case study: Superdisintegrants P Zarmpi, T Flanagan, E Meehan, J Mann, N Fotaki The AAPS journal 22, 1-17, 2020 | 43 | 2020 |
| Biopharmaceutical considerations in paediatrics with a view to the evaluation of orally administered drug products–a PEARRL review M Guimarães, M Statelova, R Holm, C Reppas, M Symilllides, M Vertzoni, ... Journal of Pharmacy and Pharmacology 71 (4), 603-642, 2019 | 36 | 2019 |
